Conference Coverage
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
Conference Coverage
Repotrectinib highly active in ROS1-positive lung cancer
Pivotal phase 2 portion of study to commence later this year.
Conference Coverage
Pembrolizumab improves 5-year OS in advanced NSCLC
CHICAGO – In a phase 1b trial of pembrolizumab, the 5-year OS rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients...
Conference Coverage
Second-line chemo sets benchmark in biliary tract cancers
CHICAGO – However, modest benefit and moderate toxicity suggest need for new treatments, especially targeted ones.
Conference Coverage
Pazopanib extended PFS in patients with carcinoid tumors
CHICAGO – Significant efficacy results need to be viewed in light of increased toxicity.
Conference Coverage
Jury still out on gemcitabine/nab-paclitaxel as treatment for pancreatic cancer
CHICAGO – Gemcitabine plus nab-paclitaxel did not extend disease-free survival versus gemcitabine alone in a phase 3 study, but overall survival...
Conference Coverage
Nephrectomy may benefit select renal cancer patients based on risk factors
CHICAGO – CARMENA update confirms cytoreductive nephrectomy should not be standard of care for most cases of metastatic renal cell carcinoma.
Conference Coverage
More liberal criteria could greatly expand clinical trial participation
CHICAGO – A proof-of-concept study suggests that broader inclusion criteria could nearly double participation in clinical trials for non–small...
Conference Coverage
MADIT-CHIC: CRT aids patients with chemotherapy-induced cardiomyopathy
Conference Coverage
FDA launches call center project to streamline Expanded Access request process
CHICAGO – Project Facilitate is a pilot call center project designed to create a single point of contact with FDA oncology staff who can guide...
Conference Coverage
Novel enfortumab vedotin induces responses in advanced urothelial cancers
CHICAGO – The investigational drug showed encouraging responses in patients with heavily pretreated locally advanced...